MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma.
Artif Cells Nanomed Biotechnol
; 46(4): 815-818, 2018 Jun.
Article
en En
| MEDLINE
| ID: mdl-28675056
BACKGROUND: Recently, microRNA-133b (miR-133b) dysregulation has been shown to play a key role in several human cancers, as well as glioma. In this study, we aimed to investigate the clinical significance and prognostic value of miR-133b in glioma. METHODS: Real-time quantitative PCR was employed to measure the expression level of miR-133b in tissues. Survival analysis was carried out by using the log-rank test and Kaplan-Meier method. Prognostic factors for overall survival were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. RESULTS: The expression level of miR-133b was significantly lower in glioma tissues compared with matched non-cancerous brain tissues (p < .05). Its level was strongly correlated with Karnofsky Performance Scale score (p < .001) and WHO grade (p < .001). Kaplan-Meier survival and log-rank analysis indicated that the decreased expression of miR-133b was strongly correlated with shorter overall survival of patients with glioma (log-rank test, p = .03). CONCLUSIONS: The current investigation demonstrated that miR-133b level is useful for predicting the prognosis of patients with glioma.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
ARN Neoplásico
/
Regulación Neoplásica de la Expresión Génica
/
MicroARNs
/
Glioma
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Artif Cells Nanomed Biotechnol
Año:
2018
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Reino Unido